# OnCo record radiomedix (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/radiomedix/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "radiomedix" ;
  schema:name "RadioMedix"@en ;
  schema:description "RadioMedix is developing AlphaMedix (212Pb-DOTAMTATE) with Orano Med, the first targeted alpha therapy to receive FDA Breakthrough designation."@en ;
  schema:url <https://onco.cc/companies/radiomedix/>, <https://www.radiomedix.com> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:citation <https://www.sanofi.com/en/media-room/press-releases/2024/2024-09-12-05-00-00-2944919> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/neuroendocrine/> ;
  onco:sections <https://onco.cc/fronts/radiopharma/> ;
  onco:technologies <https://onco.cc/technologies/targeted-alpha-therapy/> ;
  onco:targets <https://onco.cc/targets/sstr2/> ;
  onco:companies <https://onco.cc/companies/orano-med/>, <https://onco.cc/companies/sanofi/> .